Fisher & Paykel Healthcare
FPH.ASXHealth Care
Fisher & Paykel Healthcare is a world leader in medical devices and systems for use in respiratory care, acute care, surgery and in the treatment of obstructive sleep apnea. Our products are sold in more than 120 countries around the world and we estimate
Market Data
$31.170
+0.0%$18.2B
47.0x
$0.793
1.40%
+0.0%
Latest Earnings
Preliminary Final Report
26 May 2026
Fisher & Paykel Healthcare delivered strong FY2026 results with 14% revenue growth to $2.31B and 24% net profit growth to $468.5M, driven by robust Hospital segment performance (+18%) and improving gross margins (63.7%, +80bps). The company guides FY2027 revenue of $2.45-2.57B and net profit of $500-550M, reflecting continued momentum despite headwinds from US tariffs and geopolitical factors. Key points: Hospital revenue grew 18% to $1.51B with particularly strong consumables growth of 16%, demonstrating changing clinical practice is driving demand even amid subdued seasonal respiratory illness admissions; Net profit after tax surged 24% (28% in constant currency) to $468.5M, significantly outpacing revenue growth due to margin expansion and operating leverage; Gross margin improved 80bps to 63.7% (122bps in constant currency), reflecting continuous improvement initiatives despite 90bps headwind from US tariffs
Recent Announcements
Preliminary Final Report
Fisher & Paykel Healthcare delivered strong FY2026 results with 14% revenue growth to $2.31B and 24% net profit growth to $468.5M, driven by robust Hospital segment performance (+18%) and improving gross margins (63.7%, +80bps). The company guides FY2027 revenue of $2.45-2.57B and net profit of $500-550M, reflecting continued momentum despite headwinds from US tariffs and geopolitical factors. Key points: Hospital revenue grew 18% to $1.51B with particularly strong consumables growth of 16%, demonstrating changing clinical practice is driving demand even amid subdued seasonal respiratory illness admissions; Net profit after tax surged 24% (28% in constant currency) to $468.5M, significantly outpacing revenue growth due to margin expansion and operating leverage; Gross margin improved 80bps to 63.7% (122bps in constant currency), reflecting continuous improvement initiatives despite 90bps headwind from US tariffs
Becoming a substantial holder
Pinnacle Investment Management Group Limited (and its became a substantial holder (5.0145%).
FPH to announce full year results on 26 May 2026
Fisher & Paykel Healthcare Corporation Limited announced it will release its full year financial results for the year ended 31 March 2026 on 26 May 2026 at 9:00am NZST, followed by a conference call at 10:00am NZST the same day, with webcast available online.
Ceasing to be a substantial holder
Pinnacle Investment Management Group Limited (and its ceased to be a substantial holder (5.0487%).
Profit Guidance
Fisher & Paykel Healthcare raised its FY26 guidance due to favorable currency movements and strong hospital product growth. Revenue guidance increased to approximately $2.30B (from $2.17-2.27B range) and NPAT guidance lifted to $450-470M (from $410-460M range). The company highlighted good progress in changing clinical practice and improving margins through continuous improvement activities. Key points: Revenue guidance raised to ~$2.30B from previous $2.17-2.27B range due to favorable currency movements; NPAT guidance increased to $450-470M from previous $410-460M range; Good growth across full range of Hospital products continuing in second half
FPH to announce half year results on 26 November 2025
Fisher & Paykel Healthcare Corporation Limited announced it will release its half-year financial results for the period ended 30 September 2025 on 26 November 2025, with a conference call and webcast to follow at 10:00am NZDT on the same day.
Get real-time alerts for FPH
Receive AI-powered earnings summaries and instant notifications when Fisher & Paykel Healthcare releases results.
Register Free